A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-O ...
Parkinson's disease
Intervention name : ME2125 (safinamide mesilate) INN of the intervention : safinamide Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning. Intervention name : ME2125 (safinamide mesilate) INN of the intervention : safinamide Dosage And admin ...
A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Diseas ...
Parkinson's disease
Intervention name : ME2125 (safinamide mesilate) INN of the intervention : safinamide Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning. Intervention name : ME2125 (safinamide mesilate) INN of the intervention : safinamide Dosage And admin ...